Pharma Exclusives Pressreleases

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

Gilead Sciences Inc and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibodydrug conjugate ADC against a solid tumor target Through this agreement Gilead will gain access to...